COMPASS THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
COMPASS THERAPEUTICS, INC. (CMPX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.82M, a 72.77% increase year-over-year.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.07M, a 101.79% increase year-over-year.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.24M, a 43.68% decline year-over-year.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.79M, a 31.59% increase year-over-year.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.37M, a 2.24% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.56M, a 39.87% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.12M, a 14.82% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.33M, a 32.29% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.82M 10-Q · filed 2026-08-06 | $9.89M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.07M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $8.37M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.24M 10-Q · filed 2025-11-05 | $4.03M derived: sum of 2 quarters · filed 2026-08-06 | $6.54M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.79M 10-Q · filed 2026-08-06 | $5.30M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.51M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $8.56M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.20M 10-Q · filed 2025-11-05 | $4.32M derived: sum of 2 quarters · filed 2025-11-05 | $6.32M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $2.12M 10-Q · filed 2025-11-05 | $4.12M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $2.00M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $6.12M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-12 | $3.25M derived: sum of 2 quarters · filed 2024-11-12 | $4.52M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.63M 10-Q · filed 2024-11-12 | $2.90M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.27M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $5.33M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $1.29M 10-Q · filed 2023-11-09 | $2.73M derived: sum of 2 quarters · filed 2023-11-09 | $4.30M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.44M 10-Q · filed 2023-11-09 | $3.02M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.57M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $4.03M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $987.00K 10-Q · filed 2022-11-09 | $1.90M derived: sum of 2 quarters · filed 2022-11-09 | $2.84M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $908.00K 10-Q · filed 2022-11-09 | $1.86M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $948.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $4.02M 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $2.54M 10-Q · filed 2021-11-12 | $2.72M derived: sum of 2 quarters · filed 2021-11-12 | $2.97M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $183.00K 10-Q · filed 2021-11-12 | $430.00K derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $247.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $915.00K 10-K · filed 2021-03-05 | |||
| 2019-09-30 | $249.00K 10-Q · filed 2020-11-09 | $434.00K derived: sum of 2 quarters · filed 2020-11-09 | $689.00K derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $185.00K 10-Q · filed 2020-11-09 | $440.00K derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $255.00K 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |